131I SPECT/CT: a one-station imaging modality in the management of differentiated thyroid cancer

Xue, Yuezhen; Qiu, Zhong-Ling; Perotti, Germano; Salvatori, Massimo; Luo, Quan-Yong

doi:10.1007/s40336-013-0020-4

Cited by 6 publications

(4 citation statements)

References 46 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radioiodine SPET-CT imaging of well-differentiated thyroid cancer Planar and SPET gamma camera imaging with I-131 suffers from inherent poor spatial resolution and septal penetration artifacts that arise from the high energy 364 keV gamma emissions [46][47][48][49]. Despite its high spatial resolution and fine anatomical detail, CT has been used sparingly in thyroid cancer because of the effects of iodinated contrast on thyroid function; indeed, it results in decreased subsequent radioiodine uptake and, therefore, impairs I-131 treatment intent.…”

Section: Discussionmentioning

confidence: 99%

SPET–CT in thyroid cancer: a systematic review

Wong

Wale

Fig

et al. 2014

Clin Transl Imaging

View full text Add to dashboard Cite

The purpose of this study was to systematically review the utility of single-photon emission tomographycomputed tomography (SPET-CT) fusion imaging in the investigation of thyroid cancer. We performed a systematic search of the world literature on radionuclide SPET-CT imaging of thyroid cancer using the medical databases Medline (OVID) and PubMed. The following search terms were used to identify relevant studies: (a) thyroid, combined with (b) SPECT/CT or SPECT-CT or SPET/CT or SPET-CT. The electronic searches returned citations for 1,189 potentially eligible articles and 98 abstracts were reviewed for relevance by two co-authors. Thirty-one peerreviewed full articles reporting the utility, value and diagnostic performance of radioiodine SPET-CT for the imaging of well-differentiated thyroid cancer were selected. The quality of these studies was assessed using the quality assessment of diagnostic accuracy studies-2 tool.As there was heterogeneity in the studies, a systematic review analysis was conducted as our chosen research synthesis method. A total of 31 studies published between 2003 and 2014 report the utility of radioiodine SPET-CT. These studies uniformly found incremental diagnostic value of I-123 and I-131 SPET-CT over SPET and/or planar imaging. SPET-CT allows accurate characterization of radioiodine uptake in the neck and at distant sites, clarifies equivocal foci of radioactivity, improves specificity for disease, and evaluates benign physiological etiologies. Additional pilot uses of SPET-CT have been reported, e.g., for thyroid nodule evaluation, medullary thyroid cancer work-up, and investigation of lingual thyroid. Radioiodine SPET-CT fusion imaging of thyroid cancer has incremental utility, improving image interpretation as compared to planar and SPET imaging. It is likely to see more widespread application in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

SPET–CT in thyroid cancer: a systematic review

Wong

Wale

Fig

et al. 2014

Clin Transl Imaging

View full text Add to dashboard Cite

show abstract

“…Sodium-iodide symporters (NIS) located on the basolateral plasma membrane of thyrocytes leads to increased affinity for iodine and this physiologic mechanism is leveraged in radioiodine imaging and therapy (21). Whole-body scintigraphy (WBS) is commonly performed with 123Iodine to evaluate whether a suspicious or indeterminate thyroid nodule is "hot" (increased iodine uptake) or "cold" (diminished thyroid uptake) (22). Radioiodine scans are particularly useful in differentiated subtypes of thyroid cancer due to preserved NIS allowing for preferential increased accumulation of radioactive iodine in the neoplasm compared to normal thyroid tissue (Figure 3).…”

Section: Spect 123mentioning

confidence: 99%

Thyroid cancer diagnosis in the era of precision imaging

Bonjoc¹,

Young²,

Warner³

et al. 2020

J Thorac Dis

View full text Add to dashboard Cite

Thyroid cancer is the most common endocrine neoplasm and is the 12th most common cancer among all cancer types (1). The median 5-year survival rate for thyroid cancer was 98% between 2009 and 2015; however, prognosis is poor in more aggressive subtypes. For example, anaplastic thyroid cancer (ATC) accounts for less than 1% of all thyroid cancers, but the median survival is three to seven months and the 1-year survival rate is 10-20% (1,2). The incidence of thyroid cancer is almost double now than it was in 2000, accounting for 2.1% of cancer diagnoses (3,4). Between 1974 and 2013, the mean age of thyroid cancer diagnosis was 48±16. Women are more commonly affected than men, accounting for 75% of the diagnoses (5). There is increased incidence of thyroid cancer in the geriatric population who also have a worse prognosis from thyroid cancer due to increased treatment related morbidity and mortality (3). Due to the high recurrence rate in thyroid cancer (20%), the ability to distinguish recurrence from treatment related changes are key to improving survival (6). Thyroid cancer subtypesThere are four major subtypes of thyroid cancer: papillary (PTC), follicular (FTC), anaplastic (ATC), and medullary thyroid cancer (MTC) (1). Less common subtypes include: Hurthle cell carcinoma (HTC) and poorly differentiated thyroid cancer (PDTC). PTC, FTC, and HTC are well differentiated subtypes; accounting for approximately 95% of thyroid cancers (1). These subtypes generally have a better prognosis than PDTC and ATC subtypes. PTC Review Article on Role of Precision Imaging in Thoracic Disease

show abstract

“…Single-photon emission computed tomography / computed tomography (SPECT/CT) in this setting recently emerged as a valuable tool in accurately localizing sites of pathological uptake and physiological mimics of disease, thus providing more accurate diagnosis, staging and risk stratification, which in turn allows further individual adaptation management and follow-up (3,68).…”

Section: Management Of Increasing Tg Levelsmentioning

confidence: 99%

Detectable thyroglobulin with negative imaging in differentiated thyroid cancer patients

Giovanella¹,

Treglia²,

Ceriani³

et al. 2014

Nuklearmedizin

View full text Add to dashboard Cite

In the absence of autoantibodies against thyroglobulin (Tg), Tg measurement nowadays is the cornerstone of clinical management of differentiated thyroid cancer patients. DTC patients presenting with a positive Tg measurement without an anatomical correlate on anatomic imaging provide a management challenge to the attending physician. Based on the literature we will provide an overview of the most important steps to undertake in such patients and their potential clinical consequences.

show abstract

131I SPECT/CT: a one-station imaging modality in the management of differentiated thyroid cancer

Cited by 6 publications

References 46 publications

SPET–CT in thyroid cancer: a systematic review

SPET–CT in thyroid cancer: a systematic review

Thyroid cancer diagnosis in the era of precision imaging

Detectable thyroglobulin with negative imaging in differentiated thyroid cancer patients

Contact Info

Product

Resources

About